182 related articles for article (PubMed ID: 33536574)
1. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.
Buza N; Euscher ED; Matias-Guiu X; McHenry A; Oliva E; Ordulu Z; Parra-Herran C; Rottmann D; Turner BM; Wong S; Hui P
Mod Pathol; 2021 Jun; 34(6):1194-1202. PubMed ID: 33536574
[TBL] [Abstract][Full Text] [Related]
2. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Buza N; English DP; Santin AD; Hui P
Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
[TBL] [Abstract][Full Text] [Related]
3. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
4. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
[TBL] [Abstract][Full Text] [Related]
5. Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
Baez-Navarro X; van Bockstal MR; Nawawi D; Broeckx G; Colpaert C; Doebar SC; Hogenes MCH; Koop E; Lambein K; Peeters DJE; Sinke RHJA; Bastiaan van Brakel J; van der Starre-Gaal J; van der Vegt B; van de Vijver K; Vreuls CPH; Vreuls W; Westenend PJ; van Deurzen CHM
Mod Pathol; 2023 Jan; 36(1):100009. PubMed ID: 36788064
[TBL] [Abstract][Full Text] [Related]
6. Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer.
Vermij L; Singh N; Leon-Castillo A; Horeweg N; Oosting J; Carlson J; Smit V; Gilks B; Bosse T
Histopathology; 2021 Oct; 79(4):533-543. PubMed ID: 33835523
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N; Hui P
Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
[TBL] [Abstract][Full Text] [Related]
8. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Buza N
Int J Gynecol Pathol; 2021 Jan; 40(1):17-23. PubMed ID: 33290351
[TBL] [Abstract][Full Text] [Related]
9. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
10. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract][Full Text] [Related]
11. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract][Full Text] [Related]
12. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
14. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract][Full Text] [Related]
15. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
16. HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.
Shafi S; Nitta H; Shah M; Challa B; Parwani AV; Li Z
Am J Clin Pathol; 2023 May; 159(5):464-473. PubMed ID: 36857635
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
[TBL] [Abstract][Full Text] [Related]
18. Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry.
Wang J; Yoon E; Krishnamurthy S
Ann Diagn Pathol; 2024 Jun; 70():152288. PubMed ID: 38452457
[TBL] [Abstract][Full Text] [Related]
19. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens.
Tsuda H; Kurosumi M; Umemura S; Yamamoto S; Kobayashi T; Osamura RY
BMC Cancer; 2010 Oct; 10():534. PubMed ID: 20925963
[TBL] [Abstract][Full Text] [Related]
20. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Hagemann IS; Bridge JA; Tafe LJ; Hameed MR; Moncur JT; Bellizzi AM; Dolan M; Vasalos P; Kane ME; Souers RJ; Yemelyanova A
Arch Pathol Lab Med; 2023 Oct; 147(10):1148-1157. PubMed ID: 36538387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
